title: Efficacy and Safety of Topical Pidobenzone 4% as Adjuvant Treatment for Solar Lentigines: Result of a Randomized, Controlled, Clinical Trial.
abstract: OBJECTIVE
  This study aims at the evaluation of the efficacy and safety of a combination therapy based on pidobenzone 4% and fractional CO2 laser or cryotherapy in the treatment of solar lentigines and the prevention of eventual posttreatment hyperchromia.
  
  
  METHODS
  Efficacy was clinically evaluated by grading the pigmentation level with the Skin Tone Color Scale (STCS), and by grading patients' impression through a Visual Analog Scale (VAS).
  
  
  RESULTS
  Our study shows that the associated treatment was safe and that it improves the therapeutic results on solar lentigines and prevents postiatrogenic hyperpigmentation compared with physical therapy alone.
  
  
  CONCLUSIONS
  The combination of cryotherapy and pidobenzone 4% has been found to be the most useful treatment.
authors: Dermatology Unit, Department of Clinical and Molecular Medicine, Marche Polytechnic University, United Hospitals, Ancona, Italy.
authors: Anna
authors: A
authors: Campanati
authors: Melania
authors: M
authors: Giannoni
authors: Alessandro
authors: A
authors: Scalise
authors: Simona
authors: S
authors: De Blasio
authors: Angela
authors: A
authors: Giuliano
authors: Katia
authors: K
authors: Giuliodori
authors: Giulia
authors: G
authors: Ganzetti
authors: Elisa
authors: E
authors: Bolletta
authors: Giovanni
authors: G
authors: Di Benedetto
authors: Annamaria
authors: A
authors: Offidani
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017679:Cryotherapy / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006229:Hand Dermatoses / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D054020:Lasers, Gas / Q000627:therapeutic use; D007911:Lentigo / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012867:Skin / Q000473:pathology* / Q000528:radiation effects; D013472:Sunlight / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D011392:Proline; C534452:pidobenzone